Literature DB >> 6166674

Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.

J P Brown, K Nishiyama, I Hellström, K E Hellström.   

Abstract

Monoclonal antibodies were used to study p97, a human melanoma-associated antigen (MAA). Four hybridomas, designated 4.1, 96.5, 118.1, and 8.2, were obtained by fusing mouse myeloma cells with spleen cells from mice immunized with human melanoma cells. Antibodies 4.1 and 8.2 were IgG1; antibodies 96.5 and 118.1 were IgG2a. Sequential immunoprecipitation (IP) and sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that all 4 antibodies recognized the same 97 kilodalton (kD) protein. Binding studies with 125I-labeled antibody showed that antibodies 4.1 and 96.5 bound the same epitope, p97a. Antibodies 118.1 and 8.2 defined epitopes p97b and p97c, respectively. Six monoclonal antibodies (M17, L1, L10, R10, I12, and K5) specific for gp95, a kD melanoma cell surface glycoprotein were also tested. Sequential IP showed that these antibodies bound p97; p97 and gp95 are thus identical. Binding studies showed that antibody m17 bound epitope p971, and antibodies L1, L10, and R19 bound epitope p97c. Antibodies I12 and K5 defined 2 other epitopes, p97d and p97e, respectively. SDS-PAGE under nonreducing conditions indicated that p97 is monomeric, probably with intrachain disulfide bonds. Cell-surface labeling of sialic acid residues and neuraminidase digestion showed that p97 is a sialoglycoprotein. Digestion of p97 with papain or trypsin produced a stable 40 kD fragment, which expressed epitopes p971, p97b, and p97c, but not p97d or p97e.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166674

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.

Authors:  Lina Al-Akra; Dong-Hun Bae; Sumit Sahni; Michael L H Huang; Kyung Chan Park; Darius J R Lane; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2018-01-05       Impact factor: 5.157

2.  Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

Authors:  S L Hu; G D Plowman; P Sridhar; U S Stevenson; J P Brown; C D Estin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 3.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

Review 4.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 5.  Anti-idiotypic antibodies and the induction of specific tumor immunity.

Authors:  G T Nepom; K E Hellström
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  A monoclonal antibody specific for cells of the melanocyte lineage.

Authors:  C Vennegoor; P Hageman; H Van Nouhuijs; D J Ruiter; J Calafat; P J Ringens; P Rümke
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

7.  Modulation of melanoma-associated antigens by monoclonal antibodies as visualized by radioimmunoelectron microscopy and radioantibody binding assay.

Authors:  W Tilgen; S Matzku; I Kaufmann; M Engstner; J Brüggen; W Dippold; D Petzoldt
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

8.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. II. Identification of the cellular target structures by immunoprecipitation and SDS-PAGE analysis.

Authors:  S Paulie; H Koho; H Ben-Aissa; Y Hansson; M L Lundblad; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 9.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Melanoma biomarkers: Vox clamantis in deserto (Review).

Authors:  Mays Al-Shaer; Divya Gollapudi; Chris Papageorgio
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.